View in EDS PDF Full Text

TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer.

Saved in:
Bibliographic Details
Title: TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer.
Authors: Yardley DA; Sarah Cannon Research Institute, 250 25th Avenue North, Suite 100, Nashville, TN, 37203, USA. dyardley@tnonc.com.; Tennessee Oncology, Nashville, TN, USA. dyardley@tnonc.com., Arrowsmith ER; Sarah Cannon Research Institute, 250 25th Avenue North, Suite 100, Nashville, TN, 37203, USA.; Tennessee Oncology, Chattanooga, TN, USA., Daniel BR; Sarah Cannon Research Institute, 250 25th Avenue North, Suite 100, Nashville, TN, 37203, USA.; Tennessee Oncology, Chattanooga, TN, USA., Eakle J; Sarah Cannon Research Institute, 250 25th Avenue North, Suite 100, Nashville, TN, 37203, USA.; Florida Cancer Specialists, Fort Meyers, FL, USA., Brufsky A; University of Pittsburgh Medical Center, Pittsburgh, PA, USA., Drosick DR; Sarah Cannon Research Institute, 250 25th Avenue North, Suite 100, Nashville, TN, 37203, USA.; Oncology Hematology Care, Cincinnati, OH, USA., Kudrik F; Sarah Cannon Research Institute, 250 25th Avenue North, Suite 100, Nashville, TN, 37203, USA.; South Carolina Oncology Associates, Columbia, SC, USA., Bosserman LD; Wilshire Oncology Medical Group, La Verne, CA, USA., Keaton MR; Augusta Oncology Associates, Augusta, GA, USA., Goble SA; Virginia Cancer Institute, Richmond, VA, USA., Bubis JA; ICON/Cancer Specialists of North Florida, Jacksonville, FL, USA., Priego VM; Center for Cancer and Blood Disorder, Bethesda, MD, USA., Pendergrass K; Kansas City Cancer Center, Overland Park, KS, USA., Manalo Y; Costal Bend Cancer Center, Corpus Christi, TX, USA., Bury M; Cancer Research Consortium of West Michigan, Grand Rapids, MI, USA., Gravenor DS; Family Cancer Center, Memphis, TN, USA., Rodriguez GI; South Texas Oncology Hematology, San Antonio, TX, USA., Inhorn RC; Mercy Hospital, Portland, ME, USA., Young RR; Sarah Cannon Research Institute, 250 25th Avenue North, Suite 100, Nashville, TN, 37203, USA.; The Center for Cancer and Blood Disorders, Ft Worth, TX, USA., Harwin WN; Sarah Cannon Research Institute, 250 25th Avenue North, Suite 100, Nashville, TN, 37203, USA.; Florida Cancer Specialists, Fort Meyers, FL, USA., Silver C; Sarah Cannon Research Institute, 250 25th Avenue North, Suite 100, Nashville, TN, 37203, USA.; Florida Cancer Specialists, Fort Meyers, FL, USA., Hainsworth JD; Sarah Cannon Research Institute, 250 25th Avenue North, Suite 100, Nashville, TN, 37203, USA.; Tennessee Oncology, Nashville, TN, USA., Burris HA 3rd; Sarah Cannon Research Institute, 250 25th Avenue North, Suite 100, Nashville, TN, 37203, USA.; Tennessee Oncology, Nashville, TN, USA.
Source: Breast cancer research and treatment [Breast Cancer Res Treat] 2017 Aug; Vol. 164 (3), pp. 649-658. Date of Electronic Publication: 2017 May 15.
Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial
Journal Info: Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 28508185
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Yardley+DA%22">Yardley DA</searchLink>; Sarah Cannon Research Institute, 250 25th Avenue North, Suite 100, Nashville, TN, 37203, USA. dyardley@tnonc.com.; Tennessee Oncology, Nashville, TN, USA. dyardley@tnonc.com.<br /><searchLink fieldCode="AU" term="%22Arrowsmith+ER%22">Arrowsmith ER</searchLink>; Sarah Cannon Research Institute, 250 25th Avenue North, Suite 100, Nashville, TN, 37203, USA.; Tennessee Oncology, Chattanooga, TN, USA.<br /><searchLink fieldCode="AU" term="%22Daniel+BR%22">Daniel BR</searchLink>; Sarah Cannon Research Institute, 250 25th Avenue North, Suite 100, Nashville, TN, 37203, USA.; Tennessee Oncology, Chattanooga, TN, USA.<br /><searchLink fieldCode="AU" term="%22Eakle+J%22">Eakle J</searchLink>; Sarah Cannon Research Institute, 250 25th Avenue North, Suite 100, Nashville, TN, 37203, USA.; Florida Cancer Specialists, Fort Meyers, FL, USA.<br /><searchLink fieldCode="AU" term="%22Brufsky+A%22">Brufsky A</searchLink>; University of Pittsburgh Medical Center, Pittsburgh, PA, USA.<br /><searchLink fieldCode="AU" term="%22Drosick+DR%22">Drosick DR</searchLink>; Sarah Cannon Research Institute, 250 25th Avenue North, Suite 100, Nashville, TN, 37203, USA.; Oncology Hematology Care, Cincinnati, OH, USA.<br /><searchLink fieldCode="AU" term="%22Kudrik+F%22">Kudrik F</searchLink>; Sarah Cannon Research Institute, 250 25th Avenue North, Suite 100, Nashville, TN, 37203, USA.; South Carolina Oncology Associates, Columbia, SC, USA.<br /><searchLink fieldCode="AU" term="%22Bosserman+LD%22">Bosserman LD</searchLink>; Wilshire Oncology Medical Group, La Verne, CA, USA.<br /><searchLink fieldCode="AU" term="%22Keaton+MR%22">Keaton MR</searchLink>; Augusta Oncology Associates, Augusta, GA, USA.<br /><searchLink fieldCode="AU" term="%22Goble+SA%22">Goble SA</searchLink>; Virginia Cancer Institute, Richmond, VA, USA.<br /><searchLink fieldCode="AU" term="%22Bubis+JA%22">Bubis JA</searchLink>; ICON/Cancer Specialists of North Florida, Jacksonville, FL, USA.<br /><searchLink fieldCode="AU" term="%22Priego+VM%22">Priego VM</searchLink>; Center for Cancer and Blood Disorder, Bethesda, MD, USA.<br /><searchLink fieldCode="AU" term="%22Pendergrass+K%22">Pendergrass K</searchLink>; Kansas City Cancer Center, Overland Park, KS, USA.<br /><searchLink fieldCode="AU" term="%22Manalo+Y%22">Manalo Y</searchLink>; Costal Bend Cancer Center, Corpus Christi, TX, USA.<br /><searchLink fieldCode="AU" term="%22Bury+M%22">Bury M</searchLink>; Cancer Research Consortium of West Michigan, Grand Rapids, MI, USA.<br /><searchLink fieldCode="AU" term="%22Gravenor+DS%22">Gravenor DS</searchLink>; Family Cancer Center, Memphis, TN, USA.<br /><searchLink fieldCode="AU" term="%22Rodriguez+GI%22">Rodriguez GI</searchLink>; South Texas Oncology Hematology, San Antonio, TX, USA.<br /><searchLink fieldCode="AU" term="%22Inhorn+RC%22">Inhorn RC</searchLink>; Mercy Hospital, Portland, ME, USA.<br /><searchLink fieldCode="AU" term="%22Young+RR%22">Young RR</searchLink>; Sarah Cannon Research Institute, 250 25th Avenue North, Suite 100, Nashville, TN, 37203, USA.; The Center for Cancer and Blood Disorders, Ft Worth, TX, USA.<br /><searchLink fieldCode="AU" term="%22Harwin+WN%22">Harwin WN</searchLink>; Sarah Cannon Research Institute, 250 25th Avenue North, Suite 100, Nashville, TN, 37203, USA.; Florida Cancer Specialists, Fort Meyers, FL, USA.<br /><searchLink fieldCode="AU" term="%22Silver+C%22">Silver C</searchLink>; Sarah Cannon Research Institute, 250 25th Avenue North, Suite 100, Nashville, TN, 37203, USA.; Florida Cancer Specialists, Fort Meyers, FL, USA.<br /><searchLink fieldCode="AU" term="%22Hainsworth+JD%22">Hainsworth JD</searchLink>; Sarah Cannon Research Institute, 250 25th Avenue North, Suite 100, Nashville, TN, 37203, USA.; Tennessee Oncology, Nashville, TN, USA.<br /><searchLink fieldCode="AU" term="%22Burris+HA+3rd%22">Burris HA 3rd</searchLink>; Sarah Cannon Research Institute, 250 25th Avenue North, Suite 100, Nashville, TN, 37203, USA.; Tennessee Oncology, Nashville, TN, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228111104%22">Breast cancer research and treatment</searchLink> [Breast Cancer Res Treat] 2017 Aug; Vol. 164 (3), pp. 649-658. <i>Date of Electronic Publication: </i>2017 May 15.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Kluwer+Academic%22">Kluwer Academic </searchLink><i>Country of Publication: </i>Netherlands <i>NLM ID: </i>8111104 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1573-7217 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201676806%22">01676806 </searchLink><i>NLM ISO Abbreviation: </i>Breast Cancer Res Treat <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=28508185
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s10549-017-4285-6
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 649
    Titles:
      – TitleFull: TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Yardley DA
      – PersonEntity:
          Name:
            NameFull: Arrowsmith ER
      – PersonEntity:
          Name:
            NameFull: Daniel BR
      – PersonEntity:
          Name:
            NameFull: Eakle J
      – PersonEntity:
          Name:
            NameFull: Brufsky A
      – PersonEntity:
          Name:
            NameFull: Drosick DR
      – PersonEntity:
          Name:
            NameFull: Kudrik F
      – PersonEntity:
          Name:
            NameFull: Bosserman LD
      – PersonEntity:
          Name:
            NameFull: Keaton MR
      – PersonEntity:
          Name:
            NameFull: Goble SA
      – PersonEntity:
          Name:
            NameFull: Bubis JA
      – PersonEntity:
          Name:
            NameFull: Priego VM
      – PersonEntity:
          Name:
            NameFull: Pendergrass K
      – PersonEntity:
          Name:
            NameFull: Manalo Y
      – PersonEntity:
          Name:
            NameFull: Bury M
      – PersonEntity:
          Name:
            NameFull: Gravenor DS
      – PersonEntity:
          Name:
            NameFull: Rodriguez GI
      – PersonEntity:
          Name:
            NameFull: Inhorn RC
      – PersonEntity:
          Name:
            NameFull: Young RR
      – PersonEntity:
          Name:
            NameFull: Harwin WN
      – PersonEntity:
          Name:
            NameFull: Silver C
      – PersonEntity:
          Name:
            NameFull: Hainsworth JD
      – PersonEntity:
          Name:
            NameFull: Burris HA 3rd
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 08
              Text: 2017 Aug
              Type: published
              Y: 2017
          Identifiers:
            – Type: issn-electronic
              Value: 1573-7217
          Numbering:
            – Type: volume
              Value: 164
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: Breast cancer research and treatment
              Type: main
ResultId 1